Abstract:Epidermal Growth Factor Receptor variant III (EGFRvIII) is a recurrent oncogenic EGFR isoform found in 25-64% of glioblastomas, the most common form of primary brain cancer. While EGFRvIII expressing glioblastomas are initially sensitive to EGFR inhibition, emergence of resistance clones is universal. We previously demonstrated that EGFRvIII expressing glioblastoma can be ablated through inhibition of compensatory mechanisms that allow cancer cells to adapt to EGFRvIII induced oncogenic stress. Here we propose that this strategy can be combined with direct inhibition of EGFR signaling. A synthetic lethal RNAi screen revealed synthetic lethality between Polo-Like Kinase 1 (PLK1) inhibition and EGFRvIII expression in glioblastoma cells. PLK1 mediated glioblastoma adaptation to excessive DNA damage associated with EGFRvIII expression through activation of Rad51, a protein essential for homologous recombination (HR). PLK1 inhibition (by BI2536) enhanced the cytotoxic effects of the DNA damaging agent, temozolomide (TMZ), a DNA alkylating agent and the standard-of-care chemotherapy for glioblastoma. This TMZ-sensitizing effect is 3-5 fold more pronounced in a formed Ink4a/Arf(-/-) EGFRvIII GEMM (genetically engineerd murine model)-derived glioblastoma model relative to an Ink4a/Arf(-/-) PDGF-β GEMM-derived glioblastoma model and correlated to the endogenous level of DNA damage accumulation in these models. Importantly, the tumoricidal and TMZ-sensitizing effects of BI2536 were uniformly observed across Ink4a/Arf(-/-) EGFRvIII glioblastoma clones that acquired independent resistance mechanisms to EGFR inhibitors, Gefitinib and Erlotinib, suggesting these resistant clones retain oncogenic stress that required PLK1 compensation. Although BI2536 significantly augmented the anti-neoplastic effect of EGFR inhibitors in the Ink4a/Arf(-/-) EGFRvIII model, complete ablation was not achieved until TMZ was added. Such synergistic effect was not observed in the Ink4a/Arf(-/-) PDGF-β model. Our study revealed a novel synthetic lethal interaction between PLK1 inhibition and EGFRvIII expression. Our results suggest that optimal therapeutic effect against EGFRvIII expressing glioblastomas requires “multi-orthogonal” integration of oncogenic inhibition, oncogenic stress, and conventional chemotherapy, tailored to the molecular physiology associated with the target cancer genome. Citation Format: Ying Shen, Jie Li, Frank B Furnari, Arshad Desai, Hong-Zhuan Chen, Clark Chen. A multi-orthogonal strategy for targeting EGFRvIII expressing glioblastomas. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3478. doi:10.1158/1538-7445.AM2015-3478

Single-cell RNA-seq reveals RAD51AP1 as a potent mediator of EGFRvIII in human glioblastomas

Expression of Dedifferentiation Markers and Multilineage Markers in U251 Glioblastoma Cells with Silenced EGFR and FGFR Genes.

EGFR/EGFRvIII remodels the cytoskeleton via epigenetic silencing of AJAP1 in glioma cells

Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance

EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation

EGFRvIII Promotes the Proneural–Mesenchymal Transition of Glioblastoma Multiforme and Reduces Its Sensitivity to Temozolomide by Regulating the NF-κB/ALDH1A3 Axis

EGFRvIII Promotes the Proneural-Mesenchymal Transition of Glioblastoma Multiforme and Reduces Its Sensitivity to Temozolomide by Regulating the NF-?B/ALDH1A3 Axis

EGFR and EGFRvIII coopt host defense pathways, promoting progression in glioblastoma

Abstract 3478: A multi-orthogonal strategy for targeting EGFRvIII expressing glioblastomas

Dual Inhibition of Src and PLK1 Regulate Stemness and Induce Apoptosis Through Notch1-SOX2 Signaling in EGFRvIII Positive Glioma Stem Cells (Gscs).

The CRISPR/Cas9 System Targeting EGFR Exon 17 Abrogates NF-κB Activation Via Epigenetic Modulation of UBXN1 in EGFRwt/vIII Glioma Cells

A Multi-Orthogonal Strategy For Targeting Egfrviii Expressing Glioblastomas

MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII

In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature

Structural insights into the role and targeting of EGFRvIII

Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

Guanylate binding protein-1 mediates EGFRvIII and promotes glioblastoma growth in vivo but not in vitro

Effects of Combined Radiosurgery and Temozolomide Therapy on Epidermal Growth Factor Receptor and Variant III in Glioblastoma Multiforme.

In vivo functional characterization of EGFR variants identifies novel drivers of glioblastoma

EGFR Mutation Promotes Glioblastoma Through Epigenome and Transcription Factor Network Remodeling

Genome-Wide CRISPR-Cas9 Screening Identifies NF-κB/E2F6 Responsible for EGFRvIII-Associated Temozolomide Resistance in Glioblastoma.